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The molecular clones pSPeiav19 and p19/wenv17 of equine infectious anemia virus (EIAV) differ in env and
long terminal repeats (LTRs) and produce viruses (EIAV19 and EIAV17, respectively) of dramatically different
virulence phenotypes. These constructs were used to generate a series of chimeric clones to test the individual
contributions of LTR, surface (SU), and transmembrane (TM)/Rev regions to the disease potential of the
highly virulent EIAV17. The LTRs of EIAV19 and EIAV17 differ by 16 nucleotides in the transcriptional
enhancer region. The two viruses differ by 30 amino acids in SU, by 17 amino acids in TM, and by 8 amino acids
in Rev. Results from in vivo infections with chimeric clones indicate that both LTR and env of EIAV17 are
required for the development of severe acute disease. In the context of the EIAV17 LTR, SU appears to have
a greater impact on virulence than does TM. EIAV17SU, containing only the TM/Rev region from the avirulent
parent, induced acute disease in two animals, while a similar infectious dose of EIAV17TM (which derives SU
from the avirulent parent) did not. Neither EIAV17SU nor EIAV17TM produced lethal disease when adminis-
tered at infectious doses that were 6- to 30-fold higher than a lethal dose of the parental EIAV17. All chimeric
clones replicated in primary equine monocyte-derived macrophages, and there was no apparent correlation
between macrophage tropism and virulence phenotype.
Equine infectious anemia virus (EIAV) is a macrophage-
tropic lentivirus of horses (42). The virus differs from the
feline, simian, and human immunodeficiency viruses (FIV,
SIV, and HIV, respectively) in that lymphocytes are not targets
of virus replication and that infected animals do not develop
severe immunodeficiency (32). Following exposure to the virus,
an acute disease episode of relatively short duration generally
occurs within 1 week to 1 month. Acute disease is character-
ized by fever, anemia, thrombocytopenia, central nervous sys-
tem depression, and anorexia (reviewed in references 19 and
41). The acute disease episode is generally mild, but horses will
occasionally develop a particularly severe, fatal form of acute
disease that is characterized by a high-titer viremia and very
high body temperature. Animals recovering from the acute
disease episode may enter the chronic or persistent phase of
EIA, which is characterized by periodic episodes of clinical
illness. Most infected horses gain immunologic control of virus
replication, becoming inapparent carriers.
EIAV antigenic and genomic variations have been previ-
ously examined at length (1, 3, 6, 17, 18, 21, 23, 24, 33, 35, 39,
40, 45, 46). Studies of env gene variation demonstrate that
infected animals maintain the virus as a quasispecies, as has
been previously documented for other lentiviruses (17, 18, 23,
24, 26, 34, 35, 45, 46). Accumulation of mutations in specific
variable domains of the surface (SU) unit protein allows the
virus to evade or escape neutralizing antibodies (14, 15). Ge-
netic variation in other regions of the EIAV genome has also
been described previously. We and others have demonstrated
the influence of long terminal repeat (LTR) sequences on the
growth characteristics of EIAV (25, 31, 36). Genetic analysis of
rev during long-term infection suggests that rev variation may
influence virus expression, affecting long-term viral persistence
(3, 4).
Previous studies of EIAV genetic variation have focused
largely on understanding the virus-host interactions that result
in chronic disease and viral persistence rather than on defining
the determinants of virulence. For the present study, we used
infectious molecular clones of EIAV to examine the genetic
basis of two very different virulence phenotypes that have been
described previously (37, 38). EIAV19 is a virus stock derived
from the infectious molecular clone pSPeiav19. EIAV19 repli-
cates in primary fetal equine kidney, equine dermis, and
equine monocyte-derived macrophages (eMDM) as well as in
the feline embryonic adenocarcinoma and Cf2Th cell lines
(38). We have observed that EIAV19 causes no clinical disease,
even when administered to ponies at high doses (38).
To generate a genetically defined virulent virus, pSPeiav19
was used as the backbone to produce a set of clones in which
env and LTRs were replaced by sequences obtained directly
from the highly virulent Wyoming field strain of EIAV (37).
One construct, p19/wenv17, has been described previously, and
virus derived from this clone (designated EIAV17) causes se-
vere acute disease in our Shetland pony model (37). EIAV17
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replicates only in eMDM, a characteristic shared by field
strains of EIAV (5). The acute virulence phenotype of EIAV17
is useful for studies in which the availability of experimental
animals is limited.
Sequence differences between clones pSPeiav19 and p19/
wenv17 are limited to an approximately 2-kb fragment of env
and the viral LTRs. Virus stocks derived from both pSPeiav19
and p19/wenv17 replicate to a high titer, with cytopathic ef-
fects, in eMDM (37), so it is unlikely that the dramatic differ-
ence in their virulence phenotypes is due solely to macrophage
tropism. These clones provide an ideal starting point to locate
those genes or regions that play major roles in virulence. In this
report, we describe the construction and testing of several new
infectious molecular clones of EIAV that we have used to
determine the contributions of env and LTRs to the virulence
phenotype of EIAV17 and demonstrate that both SU and
LTRs contain virulence determinants.
MATERIALS AND METHODS
Clone construction. Infectious molecular clones described in this report are
depicted in Fig. 1. pSPeiav19 (Fig. 1A), p19/wenv17 (Fig. 1B), and p19/wyoLTR
(Fig. 1C) have been described previously (36–38). The new construct p17env/19
(Fig. 1D) contains an env gene fragment from p19/wenv17, but its LTRs are
derived from pSPeiav19. p17env/19 was constructed by using a combination of
PCR and conventional cloning. PCR was used to generate a 338-bp fragment
containing nucleotides (nt) 7910 to 8231 from pSPeiav19 using primers WS1
(5-TGTGGGGTTTTTATGAGGGG-3) and 8211R1 (5-CGCGGTCGACGA
ATTCTGTAGGATCTCGAACAGAC-3) (Fig. 2). Primers 7582 (5-TAAGG
ACCCTTGGTG-3) and 91 (5-GCCTAGCAACATGAGCT-3) were used to
generate a 428-bp fragment (nt 7587 to 8014) from p19/wenv17. The two PCR
products overlap by 107 identical nt between the oligonucleotides WS1 and 91.
These two products, and primers 8211R1 and 7611 (5-CCCCCCCCGTCGAC
FIG. 1. Schematic representation of clones and the EIAV genome. (A through G) Open boxes represent the sequence of pSPeiav19 (GenBank
accession number U01866 [38]). Solid black boxes represent sequences derived from the Wyoming field strain that were used to generate the
p19/wenv17 clone (GenBank accession number AF028232 [37]). Plasmid designations are shown to the left of each construct; virus designations
are shown to the right. Panel G shows the relative positions of EIAV open reading frames. The restriction enzyme sites used to generate new clones
are indicated.
FIG. 2. EIAV19 and EIAV17 LTR sequences. The underlined region is the transcriptional enhancer. The sequence differences in this region
result in the presence of a unique set of transcription factor binding sites for each virus; similar EIAV LTRs have been previously described and
mapped by others (28, 29). The arrows represent oligonucleotide primers used in PCR to facilitate the construction of p19/wyoLTR. The
numbering scheme is based on the position of the 3 LTR from clones pSPeiav19 and p19wenv/17.
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GAGATTCGAAGCGAAGG-3), were used to amplify a 636-bp fragment that
places the pSPeiav19 LTR onto the 3 end of the env region of p19/wenv17. The
636-bp fragment was digested with BstBI and EcoRI and was used to replace the
corresponding region from a 2.6-kbp (SphI to EcoRI) fragment of p19/wenv17
(37). The new 2.6-kbp SphI-to-EcoRI fragment was then moved into pSPeiav19
in order to generate p17env/19.
To construct p17Nhe1/19/wyoLTR (Fig. 1E), we started with p19/wyoLTR
(36), which had been digested with NheI to remove a 2.79-kbp pol-env fragment
(Fig. 1G). The corresponding NheI fragment was isolated from p19/wenv17 and
ligated to the prepared vector. The two NheI fragments share sequences from the
5 NheI site through the SphI site but differ from the SphI site to the 3 NheI site;
thus, the NheI fragment swap effectively places the SphI-to-3-NheI fragment
from p19/wenv17 onto the p19/wyoLTR background. Clone p19Nhe/17 (Fig. 1F)
derives sequences from the 3 NheI site through the 3 LTR from p19/wenv17.
This plasmid was prepared by starting with clone p19/wenv17, removing its
2.79-kb NheI fragment, and replacing it with the corresponding NheI fragment
from pSPeiav19. All clones were analyzed by restriction enzyme digestion and
partial DNA sequence analysis in order to check that the desired genetic swaps
and replacements were present. All clones were constructed and maintained in
a derivative of the low-copy-number vector pLG338 (10).
Virus stocks. To generate infectious virus, plasmid DNA was used to transfect
D17 cells (ATCC CCL-183) by using a calcium phosphate transfection kit (In-
vitrogen) as described previously (37), and culture supernatants were collected at
24, 48, and 72 h. Culture supernatants were tested for the presence of reverse
transcriptase (RT), as described previously (13), using [3H]TTP in place of
[32P]TTP. One-milliliter aliquots of D17 cell supernatants were passed onto
eMDM to generate virus stocks. The eMDM were recovered and maintained as
described previously (44).
The 50% infective dose (ID50) for eMDM was also determined for each virus
stock. Cells were plated in poly-D-lysine-coated 12-well dishes (BD Biosciences),
infected 4 days postplating, and maintained for 11 days postinfection (p.i.). Virus
was concentrated from culture supernatants by centrifugation; the presence of
virus was determined by RT assay. RT values of greater than three times that of
uninfected control cultures were considered positive for virus growth.
To serve as another indicator of viral infectivity, a real-time Taqman PCR
assay was used to determine the provirus copy numbers in eMDM at 24 h p.i.
Cells were lysed, and total DNA was purified by using a QIAmp tissue kit
(Qiagen). A Taqman real-time PCR assay was performed on a Bio-Rad Icycler
machine as follows. Each 50-l reaction contained 1 reaction buffer (Applied
Biosystems) without MgCl2, 5.5 mM MgCl2, 0.3 mM deoxynucleotide triphos-
phates, 0.3 M upstream primer (5-TTCCCATGACAGCAAGGTTT-3), 0.3
M downstream primer (5-TCCATTGTCTATATGTCTGCCTAAA-3), 0.07
M Taqman probe (5-FAM-CAAAAGCAGGCTCCATCTGTCTTTCTCTAG
GACT-TAMRA-3), 5 to 10 g of DNA template or water control, and 1.25 U
of AmpliTaq Gold (Applied Biosystems). Cycling parameters were 95°C for 30 s
and 58°C for 1 min (40 cycles). DNA standards consisted of pSPeiav19 plasmid
DNA at 102 to 106 molecules per reaction in duplicate. Cell DNA samples were
analyzed in duplicate, and real-time data were analyzed by using Bio-Rad Icycler
software.
Animal studies. Animal studies complied with all relevant federal guidelines
and institutional policies. Virus stocks were used to infect Shetland ponies as
previously described (37). Animals inoculated with the following virus stocks
received a virus dose of 2  105 counts per minute (cpm) of RT activity:
EIAV17E/19L, EIAV19/WYOLTR, and EIAV17TM. EIAV17SU was inoculated at a
dose of 105 cpm of RT activity.
Rectal temperatures of infected animals were monitored twice daily. Blood
samples were obtained pre- and postinfection for determination of complete
blood counts. Disease episodes were defined as periods of increased body tem-
perature. Blood and serum samples were collected to quantify virus, to monitor
the development of antiviral antibody, and for recovery of viral genomes. En-
zyme-linked immunosorbent assay (ELISA) to detect a transmembrane peptide
was performed by using a commercial assay (obtained from Centaur, Inc.). Agar
gel immunodiffusion assays were performed as described previously (9). Viral
genome fragments were amplified from blood samples collected within 2 weeks
p.i., cloned, and sequenced to confirm the identity of the infecting virus stocks.
RESULTS
In previous studies, we demonstrated a difference in the
ability of EIAV19 and EIAV17—derived from two infectious
molecular clones, pSPeiav19 and p19/wenv17, respectively—to
produce disease in Shetland ponies. EIAV19 fails to produce
clinical symptoms, even when administered to ponies at doses
of up to 106 cpm of RT activity (38). In contrast, EIAV17,
which contains env and LTR sequences derived from the Wy-
oming field strain of EIAV, induces severe disease by two
weeks p.i. when administered at 10- to 20-fold-lower doses
(37). As illustrated in Fig. 1, these two clones share approxi-
mately 5.4 kb of sequence, differing only in their LTRs (Fig. 2)
and env/rev regions (Fig. 3). Regions in common include gag,
pol, tat, S2, and the amino terminus of env. The shared env
region has a length of 438 bp, encompassing the first 146 amino
acids of the env open reading frame and the first coding exon
of rev. To further investigate the genetic region(s) responsible
for the different virulence phenotypes, we constructed addi-
tional clones combining defined regions of the pSPeiav19 and
p19/wenv17 genomes.
Contribution of env and LTR sequences to virulence pheno-
type. We first assayed the individual contributions of the Wy-
oming-derived LTR and env sequences to the virulence phe-
notype of EIAV17. We constructed p17env/19 (Fig. 1D), which
contains two complete LTRs from the avirulent clone
pSPeiav19 in combination with the env region from the viru-
lent p19/wenv17. Figure 2 shows the primers used in a PCR
strategy to facilitate the LTR replacement. The EIAV19 LTR
was swapped for the EIAV17 LTR in an identical region of 107
bp that begins just 3 to the polypurine tract. The two LTRs
differ at 16 positions that fall within the enhancer region in U3
(Fig. 2) and confer changes in previously mapped transcription
factor binding sites (28, 29). As shown in Table 1, EIAV17E/19L,
derived from clone p17env/19, replicates in eMDM to produce
a virus stock with RT activity equivalent to that of the parental
EIAV17 virus. When tested in vivo, EIAV17E/19L failed to pro-
duce a febrile episode during the first 45 days p.i. (Fig. 4B);
however, the infected animal seroconverted by day 18 p.i.
While only one animal was inoculated with EIAV17E/19L, the
virus dose (as determined by RT activity) was twofold higher
than the dose of EIAV17 that produced severe disease episodes
(requiring euthanasia) in two animals (Fig. 4A). We recently
determined ID50 titers in eMDM for each of the virus stocks
tested in animals (Table 1). By this criterion, EIAV17E/19L was
administered at an infectious dose that was 2.5-fold higher
than the lethal dose of EIAV17, suggesting that the Wyoming-
derived LTR makes an important contribution to the virulence
phenotype of EIAV17.
Clone p19/wyoLTR (Fig. 1C) derives its LTRs from the
virulent parent p19/wenv17 and derives its env/rev sequences
from the avirulent parent pSPeiav19, as described previously
(36). As shown in Table 1, EIAV19/WYOLTR, derived from
clone p19/wyoLTR, replicates in eMDM to produce virus stocks
with RT activity equivalent to that of EIAV17. EIAV19/WYOLTR
was used to infect two animals, whose clinical profiles are
shown in Fig. 4C and D. The animals seroconverted at 19 and
21 days p.i., but neither experienced a febrile episode for the
first 100 days p.i. A third animal infected with EIAV19/WYOLTR
also failed to exhibit clinical symptoms and did not
seroconvert until approximately 50 days p.i. (data not shown).
EIAV19/WYOLTR was administered to ponies at twice the lethal
dose (as measured by RT activity) of EIAV17; however, the
ID50 per cpm of this virus stock is approximately 10-fold less
than that of the EIAV17 stock. By this criterion, the infecting
dose in each of three animals was approximately 2.5-fold lower
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than a dose of EIAV17 that induced acute clinical disease;
however, none of the EIAV19/WYOLTR-infected animals devel-
oped even mild clinical disease. The combined results from
these four infections strongly suggest that both the Wyoming-
derived LTRs and the Wyoming-derived env gene each con-
tribute to the virulence phenotype of EIAV17.
Contribution of SU and TM sequences to virulence pheno-
type. EIAV17 and EIAV19 differ by 30 amino acids in SU and
17 amino acids in TM, as shown in Fig. 3. Therefore, we next
examined the relative contribution of SU versus that of the
TM/rev region to the virulence phenotype of EIAV17. We
constructed p17Nhe/19/wyoLTR and p19Nhe/17, which con-
tain only the SU or only the TM/Rev region from the virulent
parent, respectively (Fig. 1). Both constructs derive LTRs from
the virulent parent and share common gag, pol, tat, and S2
sequences with both parents. The virus derived from p17Nhe/
19/wyoLTR (designated EIAV17SU) shares amino acids 147 to
444 of SU with EIAV17. Note that the first 438 bp of SU is
shared by both the virulent and avirulent parents and that this
region encodes the first 146 amino acids of SU as well as the
first coding exon of rev (Fig. 3). The first 19 amino acids of TM
of EIAV17SU are also derived from the virulent parent, while
the remainder of TM and the second coding exon of rev are
from the avirulent parent. EIAV17SU was used to infect Shet-
land ponies (results shown in Fig. 4E and F). Both ponies
experienced acute febrile episodes. Pony E2063 had a single
febrile episode at days 10 to 12 p.i. The febrile episode re-
solved, and the animal maintained a normal body temperature
for the next 2 months. Pony E2064 also experienced acute
disease but with somewhat different characteristics. A day of
elevated body temperature was recorded on day 10 p.i. and
again at day 20 p.i. A more notable and extended febrile
episode occurred at days 30 to 32 p.i. The body temperature
then remained normal through the next 75 days p.i. While
disease episodes were observed, it should be noted that they
were less severe than those previously observed in ponies re-
ceiving EIAV17 (Fig. 4A) (37); note also that the infecting dose
of EIAV17SU, as determined by two different infectivity assays
(ID50 and initial provirus copy number), was up to 30-fold
greater than that of the EIAV17 parent (Table 1).
EIAV17TM (from construct p19Nhe/17 [Fig. 1F]) shares
amino acids 20 to 417 of TM and shares its overlapping rev
sequences with virulent EIAV17. The clinical profiles of two
animals infected with this virus are presented in Fig. 4G and H.
These animals seroconverted at 10 and 21 days p.i., similar to
the results observed for EIAV17SU-infected animals, but body
temperatures remained normal for more than 50 days p.i. Re-
sults of infectivity assays show that at an inoculum of 2  105
cpm of RT activity, the ponies received 6- to 20-fold more
infectious virus (as measured on eMDM by ID50 and provirus
FIG. 3. SU, TM, and Rev amino acid comparisons. The EIAV19 sequence is shown above; EIAV17 residues that differ are shown below. V2
through V8 indicate previously defined variable regions of EIAV SU (24). The approximate positions of the SphI and NheI restriction enzymes
used to construct EIAV17SU and EIAV17TM are shown. Coding exon 1 of rev is in the same reading frame as SU and is shown by the heavy
underline. Exon 2 of rev is in an alternate reading frame, and the translation is shown in the bracketed region.
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copy number) relative to the lethal dose of EIAV17. This find-
ing indicates that the TM/rev region alone is not sufficient to
account for the observed virulence phenotype of EIAV17. By
all criteria used to determine the titer of our virus stocks, both
EIAV17SU and EIAV17TM were administered to ponies at
doses equivalent to or higher than the lethal dose of EIAV17,
yet neither induced acute febrile episodes requiring euthana-
sia.
DISCUSSION
We generated a series of infectious molecular clones of
EIAV in order to map the major virulence determinants of this
lentivirus. Our focus was to identify genetic regions that influ-
ence the development and/or severity of acute disease. These
studies were facilitated by the availability of genetically related
clones (pSPeiav19 and p19/wenv17) that produce viruses
(EIAV19 and EIAV17) carrying different virulence phenotypes.
The parental viruses and all of the new chimeric viruses rep-
licate in eMDM with cytopathic effects. The RT titers of the
new virus constructs were generally comparable to those of the
parental clones (Table 1). Pony inocula were based upon RT
activity; however, we subsequently determined minimal infec-
tivity titers of the stocks used for the infections. ID50s per cpm
were determined by using primary eMDM from a single donor
animal. Unfortunately, the life span of eMDM under our stan-
dard culture conditions is limited to approximately 3 weeks, an
experimental endpoint that might not allow adequate compar-
ison of viruses with similar infectivity but different replication
kinetics. To attempt to address this possibility, we performed a
single experiment in which provirus copy numbers present at
24 h p.i. were determined by real-time PCR. As shown in Table
1, the relative amount of provirus at 24 h p.i. per cpm of
inoculum paralleled the ID50s per cpm for EIAV17, EIAV17SU,
and EIAV17TM. With one exception (EIAV19/WYOLTR), the
ID50s of the tested viruses were equivalent to or greater than
that of the parental EIAV17 virus. Since none of the chimeric
viruses produced disease severity equivalent to that produced
by EIAV17, it is clear that the ability to replicate in eMDM per
se is not a helpful indicator of the potential for the develop-
ment of severe acute disease by EIAV.
Our in vivo assays consisted of using a small number of
experimental animals and performing infections with high
doses of virus. Using these parameters, we showed that both
the env and LTRs derived from the Wyoming field strain were
required for the virulence phenotype of EIAV17. Replacement
of either the Wyoming-derived LTRs or env with those of the
avirulent strain yielded a virus that caused no acute disease in
our experimental system. EIAV17 and EIAV17E/19L differ only
in their LTR sequence and display dramatically different vir-
ulence phenotypes. The two LTRs have multiple sequence
differences that alter transcription factor binding motifs (Fig.
2). Detailed descriptions of EIAV LTR sequences similar to
those in the present study have been reported previously (28,
29), but to our knowledge, direct in vivo comparisons of these
two LTRs have not been described. We have previously dem-
onstrated that the Wyoming LTR neither drives transcription
of a reporter gene construct nor supports virus replication in
fibroblasts (36). This finding explains the selection of variant
LTRs (similar to the EIAV19 LTR) during adaptation to
growth in fibroblasts. It has also been shown that most field
strains of EIAV have LTRs that closely resemble the Wyoming
strain consensus and that there is little LTR variation when
virus containing a Wyoming-like LTR is examined over time in
vivo (26). Finally, Wyoming-like LTRs emerge in horses in-
fected with culture-adapted virus stocks (35). These data
strongly suggest that Wyoming-like LTR sequences are fa-
vored in vivo. Remaining unclear are the critical interactions
between viral LTR and host cell that favor the Wyoming LTR
in vivo and allow for disease expression from EIAV17 but not
EIAV17E/19L. A higher expression level in vivo in circulating
monocytes or tissue macrophages may lead to an increased
virus burden in the infected animal; however, an in vitro dif-
ference in replicative ability is not apparent. Alternatively, the
EIAV17 LTR might facilitate virus replication in cells other
than monocytes and macrophages, and this ability may con-
tribute to the virulence phenotype. In this regard, Maury et al.
(30) previously demonstrated the replication of EIAV in pri-
mary equine endothelial cells. Replication efficiency was strain
dependent, with three of four different strains replicating in
umbilical cord and renal artery endothelial cells. Interestingly,
the Wyoming strain of EIAV was the one tested strain that
failed to replicate in these cells (30). It is also possible that
subtle but important differences in the regulation of virus ex-
pression in vivo are affected by the LTR sequence. Future
fine-structure mapping studies of the EIAV LTR will be nec-
essary in order to define the contributions of specific transcrip-
tion factor binding motifs to the virulence phenotype of
EIAV17.
The LTR sequence is not the sole virulence determinant of
EIAV17; the Wyoming-derived env gene also contributes to its
virulence phenotype. Forty-seven amino acid differences are
found in the env regions EIAV17 and EIAV19. Thirty of these
are located in SU; 17 differences are found in TM. Rev se-
quences differ by eight amino acids in the second coding exon.
To delineate the differences that exert the highest impact on
virulence, we chose to examine env in the context of the Wy-
oming-derived LTR. Using a convenient NheI restriction en-
zyme site, we generated EIAV17SU, which derives SU, and the
first 19 amino acids of TM, from the virulent parent. Due to
the method of generating EIAV17, EIAV17SU shares most of
TM and all of its rev sequences with the avirulent parent. A
high dose of EIAV17SU caused acute disease in our two test
animals. However, the disease was not as severe as animals
TABLE 1. Maximum titers and relative infectivity of virus stocks
Virus designation
Maximum
RT titer
(cpm/ml)
Relative
ID50
per
cpma
Relative
provirus
copy no.
per cpmb
Pony
inoculum
(cpm)
Relative
infectious
virus dose
administered
EIAV17 10
5.0 1 1 5  104 0.5
EIAV17 10
5.0 1 1 105 1
EIAV19/WYOLTR 10
4.9 0.1 ND 2  105 0.2c
EIAV17E/19L 10
5.0 1.25 ND 2  105 2.5c
EIAV17SU 10
4.6 30 16 105 16–30d
EIAV17TM 10
4.8 10 3 2  105 6–20d
a The ID50 per cpm for the EIAV17 virus stock was 2.
b In a single experiment, the provirus copy numbers per cpm were 580 (560),
9,000 (3,600), and 1,660 (640) for EIAV17, EIAV17SU, and EIAV17TM, re-
spectively.
c Based upon ID50 determination.
d Range is based on ID50 and provirus copy number determinations.
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infected with EIAV17 (37), even though the EIAV17SU inocula,
as determined by ID50, were severalfold greater than those of
EIAV17. This finding strongly suggests that the presence of
TM/rev sequences from the avirulent parent attenuates the
overall virulence phenotype.
There are 30 amino acid differences in SU between the
avirulent virus, EIAV19, and both of the acutely virulent
viruses (EIAV17 and EIAV17SU). The clones contain very
divergent V3 sequences. V3 is the principal neutralizing
domain (PND) of EIAV (2) and is a region of extensive
sequence variation in vivo (23, 24, 35, 45, 46). Both inser-
tions and deletions in the EIAV PND are common, and
viruses that totally lack the PND have been recovered pre-
viously (24). EIAV17 and EIAV19 also differ in the previ-
ously defined V4 through V6 regions of SU (24). V4 is a
short variable region of five amino acids (NDTDT in
EIAV19 and NDSDT in EIAV17). Both viruses have a po-
tential N-linked glycosylation site in V4, and it seems un-
likely that the T-to-S substitution would play a major role in
the virulence phenotype. The V5 region of EIAV has been
defined as a 10-amino-acid sequence (24). The V5 sequence
of EIAV17, but not that of EIAV19, contains a potential
N-linked glycosylation site. Examination of V5 from animals
monitored during experimental infections reveals that V5
FIG. 4. Clinical profiles. (A) EIAV17-infected ponies. The infecting doses for ponies 38059 (E) and 29987 () were 10
5 cpm of RT activity;
pony 29990 (‚) was infected with 5  104 cpm of the same EIAV17 virus stock (37). Ponies 29987 and 38059 were euthanized at 17 and 18 days
p.i., respectively. (B) E1990 was infected with an eMDM culture supernatant containing 2  105 cpm of RT activity of EIAV17E/19L. Body
temperature remained normal for 45 days p.i. The arrow indicates the day of seroconversion as determined by ELISA. (C and D) Ponies E2057
and E2058 were infected with eMDM culture supernatants containing 2 105 cpm of RT activity of EIAV19/WYOLTR. Body temperatures remained
normal for 65 days p.i. with no other clinical abnormalities noted. Arrows indicate the days of seroconversion as determined by agar gel
immunodiffusion assay. (E and F) Ponies E2063 and E2064 were infected with 105 cpm of RT activity of EIAV17SU. (G and H) Ponies E2062 and
E2061 were infected with 2  105 cpm of RT activity of EIAV17TM. In panels E and F, elevated body temperatures indicate febrile episodes that
are typical of EIAV infection. Days of seroconversion (as determined by ELISA) are indicated by arrows.
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frequently contains an N-linked glycosylation site, though its
position within the domain may vary (23, 24, 46).
EIAV17 and EIAV19 also diverge extensively in the V6 re-
gion of SU, where they differ by 8 of 13 amino acids (positions
308 to 320). A functionally equivalent substitution of V to I
occurs near V6, at position 305, and two functionally equiva-
lent amino acid substitutions occur within V6 (Y309S and
A311I). A striking difference in V6 between EIAV19 and
EIAV17 is the presence in EIAV17 of two potential N-linked
glycosylation sites that are generated by a D-to-N substitution
at position 308 and by R-to-N and L-to-T substitutions at
positions 314 and 317. Examination of this region in persis-
tently infected animals shows a number of N-linked glycosyla-
tion sites in the V6 region that varies from 0 to 2 (23, 45, 46).
The two clones have similar V7 sequences and differ in V8 by
one amino acid.
The evolution of the V3 and V4 regions of EIAV SU have
been previously linked to the development of neutralization
resistance phenotypes during long-term infection (17), and a
neutralizing monoclonal antibody has been mapped to V5
(2)—strong indications that these regions evolve in response to
immune pressures. The V6 region of EIAV SU has not yet
been demonstrated to play a role in virus neutralization, as no
neutralizing antibodies to this region have been identified (17);
however, only a limited number of such antibodies have been
tested. There is presently little information regarding specific
functions of various SU domains. For example, cellular recep-
tors and/or coreceptors for EIAV have not been identified, and
no direct effects of purified EIAV SU on cell function or
disease processes have been reported. While the present study
suggests a role for SU in the development of acute disease,
additional studies are required so as to clarify its role in disease
expression.
Both of the acutely virulent viruses (EIAV17 and EIAV17SU)
also share the first 20 amino acids of TM. This region differs
between the virulent and avirulent viruses at two positions
(I4V and I7V) that lie in the fusion peptide of EIAV TM
(based on similarity to SIV and HIV TM proteins). As these
substitutions do not alter the hydrophobic nature of the do-
main, it would be surprising if they played a major role in the
virulence phenotype of EIAV17.
EIAV17TM shares amino acids 20 to 417 of TM (and the
second coding exon of rev) with the virulent EIAV17. Virus
derived from EIAV17TM failed to cause an acute febrile epi-
sode in either of two infected animals, suggesting that TM/Rev
is not solely responsible for the virulence phenotype of
EIAV17. Our results do suggest a role for TM/Rev in virulence,
however, as EIAV17SU is less virulent than is the EIAV17
parent. Comparison of the TM sequences between the aviru-
lent and acutely virulent viruses reveals 17 amino acid differ-
ences. None of the amino acid substitutions in TM change the
position or number of N-linked glycosylation sites, and hot
spots for variation in TM have not been noted.
The role of env sequences in lentivirus virulence has been
clearly demonstrated in simian-human immunodeficiency virus
(SHIV)-infected rhesus macaques (7, 8, 11, 12, 16, 20, 22, 27,
43). As few as 12 amino acid differences in the env sequence
are sufficient to change pathogenic potential of SHIV clones
(43). Most of the env changes that arise with increased viru-
lence are localized to gp120 variable regions; changes in the
number and position of N-linked glycosylation sites are com-
mon (7, 8, 16, 27, 43). Some measurable differences in virulent
SHIVs that have been attributed to env sequence changes
include fusogenicity, resistance to neutralization, and in-
creased replicative potential (7, 8, 43). During the present
study, we determined that infectivity of EIAV for eMDM is
not a reliable indicator of virulence. However, we have not yet
compared the replication kinetics of our virus stocks. In addi-
tion, the development of acute disease generally occurs prior
to the development of a detectable immune response; thus,
resistance to neutralization is unlikely to play a role in this
process. The possibility that other env-mediated biologic dif-
ferences correlate with virulence is currently under investiga-
tion.
All of the EIAV clones in this study are identical in the first
coding exon of rev, which specifies the nuclear export se-
quence. However there are eight amino acid differences be-
tween EIAV19 and EIAV17 in the second coding exon of rev
(Fig. 3). Belshan et al. (3, 4) analyzed the rev quasispecies
present over time in a horse infected with the Wyoming strain
of EIAV. EIAV17 rev is very similar (differing by only one
amino acid, E37G) to the predominant rev sequence in infec-
tious Wyoming virus stocks (3). This rev sequence was present
during the acute febrile episode, was not recovered during
chronic disease, and then reappeared during a long afebrile
period (3). In contrast, the rev of EIAV19 is similar to rev
variants that predominated during late-stage inapparent car-
rier infection (800 days p.i.). Both the virulent and avirulent
clones thus contain rev sequences that have been found in a
natural infection but that may confer a different replication
potential or phenotype to the virus.
We are continuing to examine the role of env in EIAV
virulence by generating additional molecular clones and by
monitoring env evolution in rapid-passage experiments.
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